DNA methylation status of KLF11, DLEC1, and KRT19 promoters in uterine leiomyoma and matched myometrial tissues.

<p>(A) DNA methylation status of 16 CpG sites in the KLF11 promoter region obtained from bisulfite sequencing of uterine leiomyoma and matched myometrial tissues. The numbers 1 to 8 on the side represent subjects from whom tissues were obtained, (#1–4) subjects were African Americans included in our original genome-wide DNA methylation study and we incorporated 4 new matched samples from Caucasian subjects (#5–8). Black circles represent methylated cytosines and white represent unmethylated cytosines. Numbers indicate the position of cytosine residues of CpGs relative to the transcription start site (+1). (B) Percent DNA methylation of the KLF11 promoter region in uterine leiomyoma and myometrial tissues, P<0.003. (C) DNA methylation status of 18 CpG sites in the DLEC1 promoter region from 3 African American (#1–3) and 4 Caucasian subjects (#4–7). (D) Percent DNA methylation of the DLEC1 promoter region in uterine leiomyoma and myometrial tissues, P<0.003. (E) DNA methylation status of 30 CpG sites in the KRT19 promoter region from 4 African American (#1–4) and 3 Caucasian subjects (#4–7). (F) Percent DNA methylation of the KRT19 promoter region in uterine leiomyoma and myometrial tissues, P<0.001.